Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502–26.

Article  PubMed  Google Scholar 

Zhang F, Sun J, Tang X, Liang Y, Jiao Q, Yu B, Dai Z, Yuan X, Li J, Yan J, Zhang Z, Fan S, Wang M, Hu H, Zhang C, Lv XB. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML. Cell Death Dis. 2022;13(7):590.

Article  PubMed  PubMed Central  Google Scholar 

Megías-Vericat JE, Montesinos P, Herrero MJ, Moscardó F, Bosó V, Martínez-Cuadrón D, Rojas L, Rodríguez-Veiga R, Boluda B, Sendra L, Cervera J, Poveda JL, Sanz MA, Aliño SF. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. Leuk Lymphoma. 2017;58(12):2880–94.

Article  PubMed  Google Scholar 

Francia RD, Crisci S, Monaco AD, Cafiero C, Re A, Iaccarino G, Filippi RD, Frigeri F, Corazzelli G, Micera A, Pinto A. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers. Cancers (Basel). 2021;13(5):966.

Article  PubMed  Google Scholar 

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23(2):256–63.

Article  CAS  PubMed  Google Scholar 

Stief SM, Hanneforth AL, Weser S, Mattes R, Carlet M, Liu WH, Bartoschek MD, Moreno HD, Oettle M, Kempf J, Vick B, Bianka Ksienzyk B, Tizazu B, Rothenberg-Thurley M, Quentmeier H, Hiddemann W, Vosberg S, Greif PA, Metzeler KH, Schotta G, Bultmann S, Jeremias I, Leonhardt H, Spiekermann K. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia. 2020;34(1):50–62.

Article  PubMed  Google Scholar 

Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol. 2022;29(9):6245–59.

Article  PubMed  PubMed Central  Google Scholar 

SEER data base: Cancer Stat Facts: leukemia—acute myeloid leukemia (AML). 2023. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed June 15 2023.

Zhang W, Qiu Y, Xie X, Fu Y, Wang L, Cai Z. B7 family members in lymphoma: promising novel targets for tumor immunotherapy? Front Oncol. 2021;11: 647526.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev. 2017;27(1):52–65.

Article  Google Scholar 

Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, Jiang L, Dai XM, Chen WQ, Lin Q, Li XZ. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Zhang W, Gui L, Yan X, Zhou X, Ma Y, Yang Z, Fang Y, Zhang H, Shi J. Expression and prognosis of the B7 family in acute myeloid leukemia. Ann Transl Med. 2021;9(20):1530.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao K, Zhou E, Schaafsma E, Zhang B, Cheng C. Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes. Cancer Med. 2023;12(5):5590–602.

Article  CAS  PubMed  Google Scholar 

Zhang Q, Ma R, Chen H, Guo W, Li Z, Xu K, Chen W. CD86 is associated with immune infiltration and immunotherapy signatures in AML and promotes its progression. J Oncol. 2023;2023:9988405.

Article  PubMed  PubMed Central  Google Scholar 

Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol. 2022;11(1):11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Yang L, Xiao M, Zhang Z, Shen J, Anuchapreeda S, Tima S, Chiampanichayakul S, Xiao Z. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway. Sci Rep. 2022;12(1):11444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen C, Liang C, Wang S, Chio C, Zhang Y, Zeng C, Chen S, Wang C, Li Y. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raneros AB, Rodriguez RM, Flórez AB, Palomo P, Colado E, Minguela A, Álvarez BS, López-Larrea C. Bromodomain protein BRD4 is an epigenetic activator of B7–H6 expression in acute myeloid leukemia. Oncoimmunology. 2021;10(1):1897294.

Article  Google Scholar 

Yang Z, Xu D, Ye X, Lin X, Zhang M, Su Y, Xie Q, Ni W. HHLA2 used as a potential prognostic and immunological biomarker and correlated with tumor microenvironment in pan-cancer. Biomed Res Int. 2022;2022:3924400.

PubMed  PubMed Central  Google Scholar 

Chapoval AI, Chapoval SP, Shcherbakova NS, Shcherbakov DN. Immune checkpoints of the B7 family. Part 1. general characteristics and first representatives: B7–1, B7–2, B7–H1, B7–H2, and B7-DC. Russ J BioorgChem. 2019;45:225–40.

Article  CAS  Google Scholar 

Amir Taghavi B, Alizadeh N, Saeedi H, Ahangar NK, Derakhshani A, Hajiasgharzadeh K, Silvestris N, Baradaran B, Brunetti O. Targeted therapy of B7 family checkpoints as an innovative approach to overcome cancer therapy resistance: a review from chemotherapy to immunotherapy. Molecules. 2022;27(11):3545.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kotsias F, Cebrian I, Alloatti A. Antigen processing and presentation. Int Rev Cell Mol Biol. 2019;348:69–121.

Article  CAS  PubMed  Google Scholar 

Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24.

Article  CAS  PubMed  Google Scholar 

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–9.

Article  CAS  PubMed  Google Scholar 

Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HN, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007;447(7143):482–6.

Article  CAS  PubMed  Google Scholar 

Jones AB, Rocco A, Lamb LS, Friedman GK, Hjelmeland AB. Regulation of NKG2D stress ligands and its relevance in cancer progression. Cancers (Basel). 2022;14(9):2339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alves da Silva PH, Xing S, Kotini AG, Papapetrou EP, Song X, Wucherpfennig KW, Mascarenhas J, Ferrari de Andrade L. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. 2022;139(2):205–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badrinath S, Dellacherie MO, Li A, Zheng S, Zhang X, Sobral M, Pyrdol JW, Smith KL, Lu Y, Haag S, Ijaz H, Connor-Stroud C, Kaisho T, Dranoff G, Yuan G, Mooney DJ, Wucherpfennig KW. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606(7916):992–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kay K, Dolcy K, Bies R, Shah D. Estimation of solid tumor doubling times from progression-free survival plots using a novel statistical approach. AAPS J. 2019;21(2):27.

Article  PubMed  Google Scholar 

Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A, Ueda T. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells. Cancer Sci. 2013;104(7):926–33.

Article  CAS